1. Home
  2. ACHV vs CRBU Comparison

ACHV vs CRBU Comparison

Compare ACHV & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

HOLD

Current Price

$2.89

Market Cap

233.2M

Sector

Health Care

ML Signal

HOLD

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$1.91

Market Cap

203.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACHV
CRBU
Founded
N/A
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.2M
203.9M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
ACHV
CRBU
Price
$2.89
$1.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$15.50
$10.75
AVG Volume (30 Days)
615.8K
1.1M
Earning Date
03-24-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.64
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.63
Revenue Next Year
$578.60
$10.93
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.84
$0.66
52 Week High
$6.03
$3.53

Technical Indicators

Market Signals
Indicator
ACHV
CRBU
Relative Strength Index (RSI) 24.33 54.37
Support Level $2.38 $1.70
Resistance Level $3.39 $2.07
Average True Range (ATR) 0.25 0.12
MACD -0.15 -0.01
Stochastic Oscillator 11.27 51.67

Price Performance

Historical Comparison
ACHV
CRBU

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Share on Social Networks: